LillyDirect: What It Is and What UK Patients Should Know

LillyDirect is a direct-to-patient healthcare platform developed by Eli Lilly and Company, the US-based pharmaceutical manufacturer. Launched exclusively in the United States, it connects patients with independent, licensed telehealth clinicians who can assess, prescribe, and arrange home delivery of Lilly-manufactured medicines — including treatments for type 2 diabetes and obesity. For UK patients who have encountered LillyDirect in the media, understanding what the platform is, which medicines it involves, and how it differs from NHS and UK-regulated prescribing pathways is essential for making safe, informed decisions about treatment.

What Is LillyDirect and How Does It Work?

LillyDirect is a US direct-to-patient platform by Eli Lilly that connects patients with independent licensed telehealth clinicians who assess, prescribe, and arrange home delivery of Lilly medicines. Eli Lilly acts as manufacturer and platform facilitator, not as the prescribing body.

LillyDirect is a direct-to-patient healthcare platform launched by Eli Lilly and Company, one of the world's largest pharmaceutical manufacturers. The platform was introduced in the United States as a way for patients to access Lilly-manufactured medicines through a streamlined digital pathway. Rather than bypassing standard prescribing safeguards, the service connects patients with independent, licensed telehealth clinicians who conduct clinical assessments, issue prescriptions where appropriate, and arrange for medicines to be dispensed and delivered directly to the patient's home.

It is important to note that LillyDirect itself does not employ the prescribing clinicians — these are independent licensed healthcare professionals operating through affiliated telehealth services. Eli Lilly's role is primarily that of the manufacturer and platform facilitator.

The model reflects a broader trend in the United States towards direct-to-consumer pharmaceutical services, which aim to reduce barriers to access within the US healthcare and insurance landscape. LillyDirect also provides educational resources and support tools to help patients manage their conditions. However, this model raises important questions around clinical oversight, continuity of care, and regulatory standards — considerations that vary significantly between countries, and particularly between the US and the UK.

Which Medications and Conditions Does LillyDirect Cover?

LillyDirect primarily covers type 2 diabetes and obesity, facilitating access to tirzepatide, dulaglutide, and Lilly insulin products. Weight management indications apply only to specifically licensed products such as Zepbound, not the entire drug class.

LillyDirect has been primarily associated with medications used in the management of type 2 diabetes and obesity — two conditions that have seen significant pharmaceutical innovation in recent years. The platform has drawn particular attention for facilitating access to Eli Lilly's incretin-based therapies, most notably:

• Tirzepatide (Mounjaro) — a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, licensed in the UK for the treatment of type 2 diabetes in adults.^[11][12] In the UK, the tirzepatide product licensed specifically for chronic weight management is Zepbound, which is a separate marketing authorisation with its own eligibility criteria.

• Dulaglutide (Trulicity) — a GLP-1 receptor agonist licensed in the UK for the management of type 2 diabetes. It is not licensed for weight management.

• Insulin products — including various formulations manufactured by Lilly.

These medications work by mimicking or enhancing the action of naturally occurring gut hormones that regulate blood glucose and appetite. GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner, suppress glucagon release, slow gastric emptying, and promote satiety — making them effective for glycaemic control.^[7][8] Weight management indications apply only to products specifically licensed for that purpose (such as Zepbound or semaglutide as Wegovy), and should not be assumed to apply to the entire drug class.

Adverse effects associated with these drug classes include nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation.^[3][4] Additional important risks include:

• Gallbladder disease (including cholelithiasis and cholecystitis)

• Dehydration and acute kidney injury, particularly if vomiting or diarrhoea is prolonged

• Hypoglycaemia, especially when used in combination with insulin or sulfonylureas

• Diabetic retinopathy complications, which may occur with rapid improvement in glycaemic control^[6]

• Pancreatitis — patients should be advised to seek urgent medical attention if they develop severe or persistent abdominal pain

• In animal studies, thyroid C-cell tumours have been observed; the clinical relevance in humans remains uncertain, but these medicines are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

These medicines are not recommended during pregnancy or breastfeeding. Women of childbearing potential should be counselled about the need for effective contraception. Patients should always be assessed and counselled about these risks by a qualified healthcare professional before commencing treatment, and any suspected side effects should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app).

Safety, Regulation, and Patient Considerations

LillyDirect raises concerns about fragmented care, as prescriptions are issued by telehealth clinicians rather than an established GP. UK patients should verify prescriber GMC registration, pharmacy GPhC registration, and CQC regulation before using any online prescribing service.

From a patient safety perspective, the LillyDirect model raises several important considerations. Because prescriptions are issued by independent telehealth clinicians rather than a patient's established GP or specialist, there is a potential risk of fragmented care — particularly for patients with complex comorbidities or those already taking multiple medications. Drug interactions, contraindications, and the need for appropriate baseline investigations may not always be comprehensively evaluated in a brief online consultation.

In the United States, the platform operates within the framework of FDA regulations and state-level medical licensing laws. In the United Kingdom, the regulatory landscape is distinct and involves several bodies with different responsibilities:

• MHRA (Medicines and Healthcare products Regulatory Agency) — responsible for licensing medicines and monitoring their safety (pharmacovigilance), including managing the Yellow Card scheme for reporting suspected adverse drug reactions

• GMC (General Medical Council) — regulates doctors, including those providing remote or online prescribing services

• CQC (Care Quality Commission) — regulates and inspects providers of online and independent healthcare services in England^[13]

• GPhC (General Pharmaceutical Council) — regulates pharmacists and registered pharmacies, including those dispensing medicines at a distance

Patients considering any online prescribing service — whether US-based or UK-based — should be aware of the following safety principles:

• Verify that the prescribing clinician is registered with the GMC (check via the GMC online register)

• Verify that any online pharmacy is registered with the GPhC (check via the GPhC online register) and displays the EU common logo for internet pharmacies

• Ensure the provider is regulated by the CQC if operating in England

• Inform your GP of any new medicines commenced through online or private services

• Be cautious of services that do not require a thorough medical history, relevant baseline investigations (such as HbA1c, renal function, weight and BMI, and a review of concomitant medicines), or ongoing monitoring

• Seek urgent medical attention if you experience severe or persistent upper abdominal pain (which may indicate pancreatitis or gallbladder disease), persistent vomiting or signs of dehydration, or sudden changes in vision

• Report suspected side effects via the MHRA Yellow Card scheme

These principles align with GMC guidance on remote prescribing, CQC standards for online healthcare providers, and NICE guidance on medicines optimisation and person-centred care.

Is LillyDirect Available in the UK?

LillyDirect is not available in the UK and operates exclusively in the United States. UK patients should access tirzepatide or other GLP-1 therapies through their GP or a GMC-registered specialist via NHS or CQC-regulated private pathways.

As of the time of writing, LillyDirect is not available in the United Kingdom. The platform was launched and operates exclusively within the United States, where the healthcare system, insurance landscape, and regulatory environment differ substantially from those in the UK. There is no official link between LillyDirect and NHS services, NICE-approved prescribing pathways, or UK-regulated online pharmacy providers.

In the UK, patients seeking access to Eli Lilly medicines do so through established NHS or private prescribing routes:

• Mounjaro (tirzepatide) has received MHRA marketing authorisation for the treatment of type 2 diabetes in adults and has been evaluated by NICE for this indication. NHS prescribing is subject to eligibility criteria, clinical assessment, and ongoing monitoring — typically coordinated through a GP or diabetes specialist.

• Zepbound (tirzepatide) is the tirzepatide product with a UK marketing authorisation for chronic weight management in adults who meet specific eligibility criteria.^[11][17] NICE has appraised tirzepatide for this indication; access via the NHS is subject to local commissioning decisions and clinical criteria.^[17][18]

• Dulaglutide (Trulicity) is available for type 2 diabetes management through NHS prescribing in line with NICE guidance.

For UK patients who have seen coverage of LillyDirect in the media or online, it is important to distinguish between US-based services and what is available domestically. Attempting to access US-based pharmaceutical platforms from the UK may carry significant risks, including receiving medicines without appropriate clinical oversight, potential customs and legal issues relating to the importation of prescription medicines, and lack of recourse if something goes wrong.

If you are interested in accessing GLP-1 or GIP/GLP-1 receptor agonist therapies in the UK, the recommended course of action is to speak with your GP or a registered specialist. They can assess your suitability, discuss the evidence base, and prescribe through a regulated, safe pathway in line with current NICE guidance and NHS commissioning frameworks. If using a private online service, ensure the provider is CQC-regulated, the prescriber is GMC-registered, and the dispensing pharmacy is GPhC-registered.

Frequently Asked Questions